Cytek Biosciences Reports $201.5 Million Revenue and $66.5 Million Net Loss for Fiscal Year 2025

**Cytek Biosciences Reports Fiscal Year 2025 Results**

Cytek Biosciences, Inc., a cell analysis solutions company, announced its financial results for the fiscal year ended December 31, 2025. The company reported total revenue of $201.5 million, a 1% increase compared to the $200.5 million reported in fiscal year 2024. Product revenue, which includes sales of instruments and consumables, decreased by 6% to $144.2 million, while service revenue increased by 21% to $57.3 million. The company's sales channel mix saw direct sales contributing $146.7 million and distributor channels accounting for $54.8 million. Customer mix showed academic and government institutions contributing $84.8 million, while biotechnology, pharmaceutical, distributors, and CROs accounted for $116.7 million.

The company's cost of sales totaled $97.0 million, resulting in a gross profit of $104.5 million and a gross margin of 52%. This compares to a gross profit of $111.1 million and a gross margin of 55% in the previous fiscal year. Operating expenses included research and development costs of $36.5 million, sales and marketing expenses of $49.4 million, and general and administrative expenses of $58.9 million. The company's loss from operations was $40.4 million, compared to a loss of $20.5 million in fiscal year 2024. Other income, net, totaled $10.5 million, primarily driven by investment income and foreign exchange gains.

Cytek reported a net loss of $66.5 million for fiscal year 2025, compared to a net loss of $6.0 million in fiscal year 2024. The increased net loss was primarily due to the recording of a $33.1 million valuation allowance against deferred tax assets, lower gross profit, increased operating expenses, and an operating and interest expense reduction related to a change in estimate of a license and royalty settlement liability in 2024. The company's cash and cash equivalents, restricted cash, and short-term investments totaled $261.5 million as of December 31, 2025. The company repurchased 3,292,588 shares of its outstanding common stock for a total cost of approximately $15.1 million at an average price per share of $4.56.

Looking ahead, Cytek plans to continue investing in research and development, commercial infrastructure, and global expansion to drive adoption of its FSP platform and expand into new markets. The company's strategy includes accelerating adoption of its solutions, continuing to innovate and offer best-in-class solutions, investing in integrated workflow solutions, and driving clinical research application development. The company's leadership team has extensive track records in the life sciences and technology sectors. As of December 31, 2025, its multidisciplinary group of over 700 employees includes employees with expertise across optics, electronics, fluidics, computer sciences, chemistry, biology, and medical sciences.